Tharimmune to Highlight TH104 at Upcoming Fall Conferences
Tharimmune, Inc. (Nasdaq: THAR), a pioneering biotechnology firm located in Red Bank, NJ, is committed to developing groundbreaking therapies for severe medical needs including inflammation and immunology. The company has recently announced its participation in a series of prominent fall conferences that will showcase its lead asset, TH104. This innovative formulation is designed to combat the effects of powerful opioids, particularly in situations where individuals may be exposed to dangerous substances like fentanyl.
Key Conference Details
The Tharimmune team will reveal exciting new findings at several important medical gatherings. First up, the American College of Gastroenterology (ACG) Annual Scientific Meeting is scheduled for October 24-29, 2025, at the Phoenix Convention Center. At this event, the team plans to discuss critical advancements surrounding TH104.
ACG Annual Meeting Schedule
During the ACG event, Tharimmune will present its research on Sunday, October 26, 2025, from 3:30 p.m. to 4:30 p.m. Pacific Time, located in the Exhibit Hall of the Phoenix Convention Center. This session aims to enlighten participants on the challenges posed by ultra-potent opioids and how TH104 can play a vital role in managing these issues.
Further Presentations Planned
The company has also secured its presence at The Liver Meeting® 2025, hosted by the American Association for the Study of Liver Diseases (AASLD), taking place from November 7 to 10, 2025, in Washington, DC. At this conference, representatives from Tharimmune will delve deeper into TH104's potential applications beyond its primary focus.
The Liver Meeting® Agenda
Tharimmune will take the stage on Monday, November 10, 2025, at 1:00 p.m. Eastern Time, in the Washington Convention Center's Exhibit Hall. The audience will have the opportunity to hear insights regarding ongoing research and patient-centered approaches that may redefine treatment protocols in liver disease.
AAPS PharmSci 360: Innovation in Focus
Additionally, Tharimmune will be present at the AAPS PharmSci 360 event, scheduled from November 9 to 12, 2025, in San Antonio, TX. This conference is pivotal for pharmaceutical scientists and aims to address both fundamental and emerging scientific challenges.
Poster Presentation Highlights
At the AAPS event, Tharimmune will take part in a Late Breaker Poster Session. This session will be a key platform for the company to share late-breaking findings that may impact the development of new therapies and drugs, emphasizing the importance of its innovative TH104 formulation.
About Tharimmune, Inc.
Tharimmune is on the cutting edge, developing a strategic array of therapeutic candidates for critical medical needs. Leading the charge is TH104, which targets respiratory and central nervous system challenges associated with extreme opioid exposure. This formulation is intended particularly for military personnel and first responders who might face hazardous environments contaminated by high-potency opioids.
Tharimmune’s research extends beyond TH104, with initiatives aimed at addressing chronic conditions like pruritus in primary biliary cholangitis. With the introduction of TH023, the company is also venturing into treatment opportunities for autoimmune diseases. Furthermore, its innovative EpiClick™ Technology is paving the way for novel biologic treatments targeting specific tumor epitopes, aiming to provide patient specific solutions.
The firm is dedicated not just to advancement in research but also to ensuring long-term value for investors. As part of its commitment to innovation, Tharimmune has secured a licensing agreement with OmniAb, Inc., enabling access to their state-of-the-art antibody discovery technology, which enhances its capabilities in creating targeted therapeutic solutions.
Frequently Asked Questions
What is Tharimmune focused on at the upcoming conferences?
Tharimmune is showcasing its lead asset TH104, focusing on addressing severe opioid exposure in various medical situations.
When is Tharimmune presenting at the ACG Annual Scientific Meeting?
Tharimmune’s presentation at the ACG Annual Scientific Meeting is scheduled for October 26, 2025, from 3:30 p.m. to 4:30 p.m. Pacific Time.
What other conferences will Tharimmune be attending?
In addition to the ACG meeting, Tharimmune will attend The Liver Meeting® 2025 and AAPS PharmSci 360.
What are the potential applications of TH104?
TH104 is being developed for several indications, including respiratory and nervous system depression due to opioid exposure, as well as chronic pruritus.
How is Tharimmune ensuring long-term value for investors?
Tharimmune is committed to innovation and development, alongside strategic partnerships that enhance its research capabilities and market potential.
